Citius Oncology, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Citius Oncology launched its lead product LYMPHIR in December 2025, but faces substantial doubt about its ability to continue as a going concern due to recurring losses and a need for significant additional funding.
NASDAQ
Citius Oncology files an amendment to its annual report on Form 10-K to include information previously omitted regarding directors, executive officers, compensation, security ownership, related transactions, and accountant fees.
NASDAQ
Citius Oncology's annual report highlights the FDA approval of LYMPHIR, its lead product, and outlines the company's financial status and future strategies.
NASDAQ
TenX Keane Acquisition's 2023 annual report outlines its financial status, merger agreement with Citius Oncology, and efforts to extend its business combination deadline.